
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9145974/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Case Report: A Peculiar Case of Inflammatory Colitis After SARS-CoV-2 Infection. Frontiers in Immunology, 2022, 13, 849140.	4.8	5
2	Lack of DOCK8 impairs the primary biologic functions of human NK cells and abrogates CCR7 surface expression in a WASP-independent manner. Clinical Immunology, 2022, 237, 108974.	3.2	2
3	NK Cell-Based Immunotherapy in Colorectal Cancer. Vaccines, 2022, 10, 1033.	4.4	10
4	Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nature Communications, 2022, 13, .	12.8	45
5	Amphioxus neuroglia: Molecular characterization and evidence for early compartmentalization of the developing nerve cord. Clia, 2021, 69, 1654-1678.	4.9	12
6	Human primed ILCPs support endothelial activation through NF- $\hat{\mathbb{P}}$ B signaling. ELife, 2021, 10, .	6.0	7
7	New Insights into Endometrial Cancer. Cancers, 2021, 13, 1496.	3.7	30
8	Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT. JCI Insight, 2021, 6, .	5.0	19
9	Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. European Journal of Cancer, 2021, 159, 105-112.	2.8	36
10	NKG2A expression identifies a subset of human Vδ2 TÂcells exerting the highest antitumor effector functions. Cell Reports, 2021, 37, 109871.	6.4	30
11	Untimely TGFÎ ² responses in COVID-19 limit antiviral functions of NK cells. Nature, 2021, 600, 295-301.	27.8	146
12	Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells. Frontiers in Immunology, 2021, 12, 753890.	4.8	3
13	Functional Conservation and Genetic Divergence of Chordate Glycinergic Neurotransmission: Insights from Amphioxus Glycine Transporters. Cells, 2021, 10, 3392.	4.1	3
14	Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes. Cancers, 2020, 12, 3504.	3.7	30
15	Natural killer cell impairment in ovarian clear cell carcinoma. Journal of Leukocyte Biology, 2020, 108, 1425-1434.	3.3	3
16	Role of the Main Non HLA-Specific Activating NK Receptors in Pancreatic, Colorectal and Gastric Tumors Surveillance. Cancers, 2020, 12, 3705.	3.7	10
17	Female Malignancies and Immunotherapy: What's New?. Cancers, 2020, 12, 2909.	3.7	1
18	miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 2020, 8, 119.	3.7	26

#	Article	IF	CITATIONS
19	Comprehensive Phenotyping of Human PB NK Cells by Flow Cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 891-899.	1.5	21
20	Different Features of Tumor-Associated NK Cells in Patients With Low-Grade or High-Grade Peritoneal Carcinomatosis. Frontiers in Immunology, 2019, 10, 1963.	4.8	21
21	Downregulation of HLA Class I Renders Inflammatory Neutrophils More Susceptible to NK Cell-Induced Apoptosis. Frontiers in Immunology, 2019, 10, 2444.	4.8	12
22	PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells. Frontiers in Immunology, 2019, 10, 1242.	4.8	130
23	An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More. Frontiers in Immunology, 2019, 10, 1415.	4.8	57
24	NK cells to cure cancer. Seminars in Immunology, 2019, 41, 101272.	5.6	70
25	Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. Cancer Immunology Research, 2019, 7, 841-852.	3.4	47
26	Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 890.	4.1	34
27	PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua. Mucosal Immunology, 2019, 12, 624-631.	6.0	45
28	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. Blood Advances, 2019, 3, 3674-3687.	5.2	40
29	Harnessing NK Cells for Cancer Treatment. Frontiers in Immunology, 2019, 10, 2836.	4.8	66
30	PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. Oncolmmunology, 2019, 8, 1557030.	4.6	76
31	Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immuneâ€therapeutic strategies in cancer therapy. Journal of Leukocyte Biology, 2019, 105, 1243-1251.	3.3	37
32	NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer. JCI Insight, 2019, 4, .	5.0	77
33	Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma. Blood, 2019, 134, 3231-3231.	1.4	0
34	The early expansion of anergic NKG2A ^{pos} /CD56 ^{dim} /CD16 ^{neg} natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation. Haematologica, 2018, 103, 1390-1402.	3.5	61
35	New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression. Frontiers in Immunology, 2018, 9, 2360.	4.8	47
36	Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma. Blood, 2018, 132, 4598-4598.	1.4	2

#	Article	IF	CITATIONS
37	Abstract 3786: ILC-k: Human innate lymphoid cells displaying unique metabolic features and KIR-independent cytotoxicity, impaired in acute myeloid leukemia. , 2018, , .		0
38	Identification of a subset of human natural killer cells expressing high levels of programmed death 1: AÂphenotypic and functional characterization. Journal of Allergy and Clinical Immunology, 2017, 139, 335-346.e3.	2.9	379
39	Markers and function of human NK cells in normal and pathological conditions. Cytometry Part B - Clinical Cytometry, 2017, 92, 100-114.	1.5	110
40	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature Communications, 2017, 8, 593.	12.8	175
41	The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands. Frontiers in Immunology, 2017, 8, 510.	4.8	29
42	Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. Frontiers in Immunology, 2017, 8, 798.	4.8	41
43	Editorial: NK Cell Subsets in Health and Disease: New Developments. Frontiers in Immunology, 2017, 8, 1363.	4.8	35
44	Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. Frontiers in Immunology, 2016, 7, 606.	4.8	88
45	Features of Memory-Like and PD-1+ Human NK Cell Subsets. Frontiers in Immunology, 2016, 7, 351.	4.8	107
46	Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor. Frontiers in Immunology, 2016, 7, 414.	4.8	45
47	Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis. Journal of Autoimmunity, 2016, 72, 8-18.	6.5	95
48	Cognate HLA absence in trans diminishes human NK cell education. Journal of Clinical Investigation, 2016, 126, 3772-3782.	8.2	33
49	Uptake of CCR7 by KIR2DS4+NK Cells Is Induced upon Recognition of Certain HLA-C Alleles. Journal of Immunology Research, 2015, 2015, 1-10.	2.2	21
50	TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses. Journal of Immunology, 2015, 195, 1121-1128.	0.8	48
51	Priming of Human Resting NK Cells by Autologous M1 Macrophages via the Engagement of IL-1β, IFN-β, and IL-15 Pathways. Journal of Immunology, 2015, 195, 2818-2828.	0.8	90
52	Role of the 2B4 Receptor in CD8 ⁺ T-Cell-Dependent Immune Control of Epstein-Barr Virus Infection in Mice With Reconstituted Human Immune System Components. Journal of Infectious Diseases, 2015, 212, 803-807.	4.0	30
53	B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncolmmunology, 2015, 4, e1001224.	4.6	137
54	Primitive Neuroectodermal Tumor in an Ovarian Cystic Teratoma: Natural Killer and Neuroblastoma Cell Analysis. Case Reports in Oncology, 2014, 7, 70-78.	0.7	12

#	Article	IF	CITATIONS
55	TLR/NCR/KIR: Which One to Use and When?. Frontiers in Immunology, 2014, 5, 105.	4.8	77
56	NK Cell Subset Redistribution during the Course of Viral Infections. Frontiers in Immunology, 2014, 5, 390.	4.8	64
57	Human NK cell response to pathogens. Seminars in Immunology, 2014, 26, 152-160.	5.6	71
58	Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity. Journal of Neuroimmunology, 2014, 275, 54-55.	2.3	0
59	Human Natural Killer Cells Prevent Infectious Mononucleosis Features by Targeting Lytic Epstein-Barr Virus Infection. Cell Reports, 2013, 5, 1489-1498.	6.4	196
60	KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts. Blood, 2013, 121, 3396-3401.	1.4	46
61	Human NK Cells Induce Neutrophil Apoptosis via an NKp46- and Fas-Dependent Mechanism. Journal of Immunology, 2012, 188, 1668-1674.	0.8	96
62	NK/DC Crosstalk in Anti-viral Response. Advances in Experimental Medicine and Biology, 2012, 946, 295-308.	1.6	36
63	Killer Ig–like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood, 2011, 117, 764-771.	1.4	218
64	NK cells and their receptors during viral infections. Immunotherapy, 2011, 3, 1075-1086.	2.0	25
65	Role of alloreactive KIR2DS1+ NK cells in haploidentical hematopoietic stem cell transplantation. Journal of Leukocyte Biology, 2011, 90, 661-667.	3.3	21
66	Bridging Innate NK Cell Functions with Adaptive Immunity. Advances in Experimental Medicine and Biology, 2011, 780, 45-55.	1.6	32
67	Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection. Aids, 2010, 24, 27-34.	2.2	139
68	Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. Blood, 2009, 114, 4108-4116.	1.4	84
69	The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer–cell subsets associated with high levels of HIV-1 viremia. Blood, 2009, 114, 3822-3830.	1.4	132
70	THE NK/DC COMPLOT. Advances in Experimental Medicine and Biology, 2009, 633, 7-16.	1.6	8
71	NK cells at the interface between innate and adaptive immunity. Cell Death and Differentiation, 2008, 15, 226-233.	11.2	291
72	Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC. International Immunology, 2008, 20, 1155-1167.	4.0	110

#	Article	IF	CITATIONS
73	Lysis of Endogenously Infected CD4+ T Cell Blasts by rIL-2 Activated Autologous Natural Killer Cells from HIV-Infected Viremic Individuals. PLoS Pathogens, 2008, 4, e1000101.	4.7	88
74	Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood, 2008, 112, 1776-1783.	1.4	123
75	The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood, 2007, 109, 3625-3632.	1.4	336
76	It's Only Innate Immunity But I Like it. Advances in Experimental Medicine and Biology, 2007, 590, 89-101.	1.6	4
77	In the Thick of the Fray: NK Cells in Inflamed Tissues. , 2007, 598, 12-19.		1
78	Multi-directional cross-regulation of NK cell function during innate immune responses. Transplant Immunology, 2006, 17, 16-19.	1.2	45
79	Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood, 2006, 107, 4857-4864.	1.4	136
80	Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. Journal of Experimental Medicine, 2006, 203, 2339-2350.	8.5	162
81	Identification of NKG2A and NKp80 as specific natural killer cell markers in rhesus and pigtailed monkeys. Blood, 2005, 106, 1718-1725.	1.4	65
82	NK–DC interaction: On the usefulness of auto-aggression. Autoimmunity Reviews, 2005, 4, 520-525.	5.8	54
83	Characterization of CD56 [–] /CD16 ⁺ natural killer (NK) cells: A highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2886-2891.	7.1	511
84	IL-12 or IL-4 Prime Human NK Cells to Mediate Functionally Divergent Interactions with Dendritic Cells or Tumors. Journal of Immunology, 2005, 174, 3992-3998.	0.8	117
85	Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends in Immunology, 2005, 26, 668-675.	6.8	157
86	Pathogen-induced private conversations between natural killer and dendritic cells. Trends in Microbiology, 2005, 13, 128-136.	7.7	82
87	Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells. European Journal of Immunology, 2004, 34, 1663-1672.	2.9	90
88	NK cells: innate immunity against hematological malignancies?. Trends in Immunology, 2004, 25, 328-333.	6.8	65
89	Selective cross-talk among natural cytotoxicity receptors in human natural killer cells. European Journal of Immunology, 2003, 33, 1235-1241.	2.9	77
90	CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity. European Journal of Immunology, 2003, 33, 3367-3376.	2.9	77

#	Article	IF	CITATIONS
91	IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. European Journal of Immunology, 2003, 33, 3439-3447.	2.9	166
92	Natural killer cells in HIV-1 infection: Dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15011-15016.	7.1	355
93	Natural Killer Cell-triggering Receptors in Patients with Acute Leukaemia. Leukemia and Lymphoma, 2003, 44, 1683-1689.	1.3	17
94	Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4120-4125.	7.1	588
95	Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4526-4531.	7.1	174
96	Defective expression and function of natural killer cell–triggering receptors in patients with acute myeloid leukemia. Blood, 2002, 99, 3661-3667.	1.4	434
97	Gntb-A, a Novel Sh2d1a-Associated Surface Molecule Contributing to the Inability of Natural Killer Cells to Kill Epstein-Barr Virus–Infected B Cells in X-Linked Lymphoproliferative Disease. Journal of Experimental Medicine, 2001, 194, 235-246.	8.5	287
98	2B4 functions as a co-receptor in human NK cell activation. European Journal of Immunology, 2000, 30, 787-793.	2.9	202
99	Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. Journal of Neuroimmunology, 2000, 107, 220-225.	2.3	103
100	Triggering receptors involved in natural killer cell-mediated cytotoxicity against choriocarcinoma cell lines. Human Immunology, 2000, 61, 1055-1058.	2.4	71
101	Identification and Molecular Characterization of Nkp30, a Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells. Journal of Experimental Medicine, 1999, 190, 1505-1516.	8.5	664
102	NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. European Journal of Immunology, 1999, 29, 1656-1666.	2.9	392
103	Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. European Journal of Immunology, 1999, 29, 3148-3159.	2.9	135
104	NKp44, a Novel Triggering Surface Molecule Specifically Expressed by Activated Natural Killer Cells, Is Involved in Non–Major Histocompatibility Complex–restricted Tumor Cell Lysis. Journal of Experimental Medicine, 1998, 187, 2065-2072.	8.5	641
105	CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies. European lournal of Immunology, 1996, 26, 2487-2492.	2.9	130